Advertisement

AIDS and Behavior

, Volume 22, Issue 4, pp 1184–1189 | Cite as

Will Gay and Bisexual Men Taking Oral Pre-exposure Prophylaxis (PrEP) Switch to Long-Acting Injectable PrEP Should It Become Available?

  • Steven A. John
  • Thomas H. F. Whitfield
  • H. Jonathon Rendina
  • Jeffrey T. Parsons
  • Christian Grov
Brief Report

Abstract

Oral pre-exposure prophylaxis (PrEP) is highly effective at reducing HIV transmission risk and is CDC recommended for many gay, bisexual, and other men who have sex with men (GBM). We sought to investigate awareness of and preference for using long-acting injectable PrEP (LAI-PrEP) among GBM currently taking oral PrEP (n = 104), and identify their concerns. About half of GBM had heard of LAI-PrEP, and 30.8% specifically preferred LAI-PrEP. GBM with more concerns about the level of protection and drug half-life of LAI-PrEP had lower odds of preferring LAI-PrEP. Given that daily pill adherence is a challenge for some on PrEP, it is important to investigate the degree to which those on PrEP might consider LAI-PrEP as an alternative.

Keywords

Pre-exposure prophylaxis Long-acting injectable Men who have sex with men HIV 

Resumen

La Profilaxis pre-Exposición (PrEP) es altamente efectiva en reducir el riesgo de transmisión del VIH y la es recomendada por los Centros de Control y Prevención de Enfermedades (CDC, por su sigla en inglés) para hombres homosexuales, bisexuales, y otros hombres que tienen relaciones sexuales con hombres (HGB). Buscamos investigar el grado de conciencia sobre y la preferencia por usar la PrEP inyectable de acción prolongada (LAI-PrEP, por su sigla en inglés) entre HGB que están actualmente tomando la PrEP oralmente (n = 104), e identificar sus preocupaciones al respecto. Aproximadamente la mitad de los HGB había oído sobre la LAI-PrEP (LAI-PrEP, por su sigla en inglés) y el 30.8% prefirió específicamente la LAI-PrEP. HGB con más preocupación sobre el nivel de protección y la vida-media de la LAI-PrEP tuvieron menor probabilidad de preferir la LAI-PrEP. Dado que la adherencia al tratamiento con un medicamento diario es un desafío para algunas personas que toman la PrEP, es importante investigar hasta qué punto las personas que toman la PrEP considerarían la LAI-PrEP como una alternativa.

Notes

Acknowledgments

Funding support for the PrEP & Me study and authors of this manuscript came from the National Institute of Drug Abuse (NIDA) (R21-DA039019, PI: Grov). H. Jonathon Rendina is funded by a career development award from the National Institute on Drug Abuse (K01-DA039030). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (NIH). The authors would like to acknowledge the contributions of the other members of the PrEP & Me study team (Mark Pawson, Brian Salfas, Chloe Mirzayi, Juan Castiblanco, and Ruben Jimenez) and other staff from the Center for HIV/AIDS Educational Studies and Training (Chris Hietikko, Tina Koo, Carlos Ponton, and Paula Bertone). Finally, we thank Shoshana Kahana at NIDA and all of our participants who participated in PrEP & Me. NIDA/NIH had no role in the production of this manuscript nor necessarily endorses its findings.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    CDC. HIV surveillance report, 2015, vol. 27. 2016. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.
  2. 2.
    USFDA. FDA approves first medication to reduce HIV risk. 2012. http://www.fda.gov/forconsumers/consumerupdates/ucm311821.htm.
  3. 3.
    CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States 2014. A clinical practice guideline. 2014. http://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf.
  4. 4.
    Lieb S, Thompson DR, Misra S, et al. Estimating populations of men who have sex with men in the southern United States. J Urban Health. 2009;86(6):887–901.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Parsons JT, Rendina HJ, Lassiter JM, Whitfield THF, Starks TJ, Grov C. Uptake of HIV pre-exposure prophylaxis (PrEP) in a national cohort of gay and bisexual men in the United States: the Motivational PrEP Cascade. J Acquir Immune Defic Syndr. 2017;74(3):285–92.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Mera R, McCallister S, Palmer B, Mayer G, Magnuson D, Rawlings K. Truvada (TVD) for HIV pre-exposure prophylaxis (PrEP) utilization in the United States (2013-2015). In: 21st international AIDS conference, Durban, Africa. 2016.Google Scholar
  7. 7.
    Buchbinder S, Liu A. CROI 2016: hot spots in HIV infection and advances in HIV prevention. Top Antivir Med. 2016;24(1):10–28.PubMedGoogle Scholar
  8. 8.
    Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDs. 2013;27(4):248–54.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Roberts ST, Heffron R, Ngure K, et al. Preferences for daily or intermittent pre-exposure prophylaxis regimens and ability to anticipate sex among HIV uninfected members of Kenyan HIV serodiscordant couples. AIDS Behav. 2014;18(9):1701–11.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Greene GJ, Swann G, Fought AJ, et al. Preferences for long-acting pre-exposure prophylaxis (PrEP), daily oral PrEP, or condoms for HIV prevention among U.S. men who have sex with men. AIDS Behav. 2016;21(5):1336–49.CrossRefGoogle Scholar
  11. 11.
    Parsons JT, Rendina HJ, Whitfield TH, Grov C. Familiarity with and preferences for oral and long-acting injectable HIV pre-exposure prophylaxis (PrEP) in a national sample of gay and bisexual men in the US. AIDS Behav. 2016;20(7):1390–9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Meyers K, Rodriguez K, Moeller RW, Gratch I, Markowitz M, Halkitis PN. High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy. PLoS ONE. 2014;9(12):e114700.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Steven A. John
    • 1
  • Thomas H. F. Whitfield
    • 1
    • 2
  • H. Jonathon Rendina
    • 1
    • 2
    • 3
  • Jeffrey T. Parsons
    • 1
    • 2
    • 3
  • Christian Grov
    • 4
  1. 1.Center for HIV/AIDS Educational Studies & TrainingHunter College of the City University of New York (CUNY)New YorkUSA
  2. 2.Health Psychology and Clinical Science Doctoral ProgramThe Graduate Center of the City University of New York (CUNY)New YorkUSA
  3. 3.Department of PsychologyHunter College of the City University of New York (CUNY)New YorkUSA
  4. 4.CUNY Graduate School of Public Health and Health PolicyNew YorkUSA

Personalised recommendations